619 reports of this reaction
3.9% of all TESTOSTERONE CYPIONATE reports
#3 most reported adverse reaction
DEEP VEIN THROMBOSIS is the #3 most commonly reported adverse reaction for TESTOSTERONE CYPIONATE, manufactured by Pharmacia & Upjohn Company LLC. There are 619 FDA adverse event reports linking TESTOSTERONE CYPIONATE to DEEP VEIN THROMBOSIS. This represents approximately 3.9% of all 15,890 adverse event reports for this drug.
Patients taking TESTOSTERONE CYPIONATE who experience deep vein thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEEP VEIN THROMBOSIS is moderately reported among TESTOSTERONE CYPIONATE users, representing a notable but not dominant share of adverse events.
In addition to deep vein thrombosis, the following adverse reactions have been reported for TESTOSTERONE CYPIONATE:
The following drugs have also been linked to deep vein thrombosis in FDA adverse event reports:
DEEP VEIN THROMBOSIS has been reported as an adverse event in 619 FDA reports for TESTOSTERONE CYPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEEP VEIN THROMBOSIS accounts for approximately 3.9% of all adverse event reports for TESTOSTERONE CYPIONATE, making it one of the most commonly reported side effect.
If you experience deep vein thrombosis while taking TESTOSTERONE CYPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.